-
Innovation Ranking
NewInnovation Ranking – Beam Therapeutics Inc
Beam Therapeutics Inc (Beam Therapeutics) is a biotechnology company. The company develops precision genetic medicines to treat serious genetic diseases. It is investigating BEAM-101 targeting sickle cell disease and beta-thalassemia, BEAM-102 against sickle cell disease and BEAM-201 for the treatment of T-cell acute lymphoblastic leukemia. Beam Therapeutics is also evaluating therapies against acute myeloid leukemia, alpha 1 antitrypsin deficiency, glycogen storage disorder 1a and Stargardt disease. It utilizes the REPAIR system for A-to-I (adenosine to inosine) RNA (Ribonucleic acid) editing...
-
Thematic Analysis
NewRNA-Based Drugs and the Impact of COVID-19
This report investigates the past, current and future landscape of RNA-Based drugs, and how the success of the COVID-19 vaccines may have impacted this. High level analysis of the key trends and movements within the pharmaceutical industry in reference to RNA technology is provided, allowing you to identify and discern the key points within this area.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Hyaluronidase (Recombinant, Human) + Immune Globulin (Human)) in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Hyaluronidase (Recombinant, Human) + Immune Globulin (Human)) in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Hyaluronidase (Recombinant, Human) + Immune Globulin...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BEAM-101 in Beta Thalassaemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BEAM-101 in Beta Thalassaemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BEAM-101 in Beta Thalassaemia Drug Details: BEAM-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaptesed Pegol in Metastatic Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Olaptesed Pegol in Metastatic Pancreatic Cancer Drug Details: Olaptesed pegol (NOX-A12) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orca-Q in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orca-Q in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orca-Q in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
Thalassemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Thalassemia - Drugs In Development, 2023’, provides an overview of the Thalassemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Beta Thalassaemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Beta Thalassaemia - Drugs In Development, 2023’, provides an overview of the Beta Thalassaemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Beta Thalassaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Alpha-1 Antitrypsin Deficiency (A1AD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Alpha-1 Antitrypsin Deficiency (A1AD) - Drugs In Development, 2023’, provides an overview of the Alpha-1 Antitrypsin Deficiency (A1AD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...